Ophthalmology News

Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy, to strengthen its clinical-stage pipeline, according to a press release.

The K8 implant, a first-in-class dual inflammasome inhibitor, demonstrated positive efficacy and safety at 3 months in five patients with bilateral geographic atrophy, according to a press release from Inflammasome Therapeutics.

Stand-alone canaloplasty and trabeculotomy with the Omni surgical system showed positive real-world outcomes in reducing IOP and medication use, according to a study published in American Journal of Ophthalmology.

Linsitinib, an oral small molecule under development for the treatment of thyroid eye disease, demonstrated proptosis reduction and safety in the phase 2b/3 LIDS trial, according to a press release from Sling Therapeutics.

Bausch + Lomb launched the enVista Aspire monofocal and toric IOLs in the European Union, according to a press release.

CHICAGO — In this video, Clement K. Chan, MD, FACS, discusses highlights from the AAO meeting, including presentations on pegcetacoplan and avacincaptad pegol for the treatment of geographic atrophy.

The foveal avascular zone, or FAZ, area deteriorated at 12 months in eyes with stable laser-treated proliferative diabetic retinopathy and macular capillary nonperfusion, but vision loss was not common, according to a study.

Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments for age-related macular degeneration, according to a press release.

As physicians, we have all borne witness to patients dying at a young age, whether from an unforeseen illness or injury.